Mesenchymal stem cells business – importance of informed consent
Authors:
P. Netočný 1; A. Obert 2; V. Rotrekl 3
Authors‘ workplace:
Nemocnice Šumperk a. s., Ortopedické oddělení, Primář: MUDr. Ján Debre, Ph. D.
1; Lékařská fakulta Masarykovy univerzity v Brně, Děkan: prof. MUDr. Martin Repko, Ph. D.
2; Biologický ústav Lékařské fakulty Masarykovy univerzity v Brně, Přednosta: prof. RNDr. Ondřej Slabý, Ph. D.
3
Published in:
Prakt. Lék. 2021; 101(6): 309-216
Category:
Of different specialties
Overview
The field of mesenchymal stem cells (MSCs) is becoming a relevant medical topic with the potential to turn some treatment algorithms "upside down". Apart from a few officially approved products, many private providers have decided to bring these options into the healthcare system and bring them closer to patients. Due to the rapidly evolving knowledge of the mechanism of action of MSCs, many patients may be imperfectly informed about the risks and benefits of treatment. In addition, the marketing of some private providers may amplify incomplete or false knowledge assumptions that the public has. The provision of MSCs therapies affects and is likely to significantly affect the entire Czech Republic in the future. Addressing this issue should not be based solely on regulatory authorities. We believe that it should also be addressed by all doctors and especially by general practitioners. This article provides basic information on the issue of MSCs therapies in a form that can contribute to patient awareness through physicians. By the year 2019, more than 55,000 publications on the topic of mesenchymal stem cells were published since their first isolation in 1992 and MSCs have been applied to over 10,000 patients in clinical trials. At the beginning of March 2021, according to the domain https:// www.clinicaltrialsregister.eu/ using the term "mesenchymal stem cells", there where 90 ongoing clinical trials throughout the EU and the European Economic Area (EEA) at the time of writing.
Keywords:
informed consent – mesenchymal stem cells – Marketing – medical tourism – business
Sources
1. Pittenger MF, Discher DE, Péault BM, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. Npj Regen Med 2019; 4(1): 1–15.
2. Caplan AI. Mesenchymal stem cells: time to change the name! STEM CELLS Transl Med 2017; 6(6): 1445–1451.
3. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7(5): 393–395.
4. Nogués CS, Creane M. Mesenchymal stem cells: the „other“ bone marrow stem cells. In: EuroStemCell.org [online]. Dostupné z: https://www.eurostemcell.org/mesenchymal-stem-cells-other- -bone-marrow-stem-cells [cit. 2021-03-03].
5. Han Y, Li X, Zhang Y, et al. Mesenchymal stem cells for regenerative medicine. Cells 2019; 8(8): 886.
6. Samsonraj RM, Raghunath M, Nurcombe V, et al. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med 2017; 6(12): 2173–2185.
7. Wang LT, Ting CH, Yen ML, et al. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation- -mediated diseases: review of current clinical trials. J Biomed Sci 2016; 23(1): 76.
8. Syková E, Rychmach P, Drahorádová I, et al. Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase I/IIa clinical trial. Cell Transplant 2017; 26(4): 647–658.
9. Orozco L, Munar A, Soler R, et al. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. Transplantation 2013; 95(12): 1535–1541.
10. European Medicines Agency, Comittee for Medicinal Products for Human Use. Guideline on human cell-based medicinal products [online]. Londýn: 21. 5. 2008. Dostupné z: https://www.ema. europa.eu/en/documents/scientific-guideline/guideline-humancell- based-medicinal-products_en.pdf [cit. 2021-03-04].
11. Iijima H, Isho T, Kuroki H, et al. Effectiveness of mesenchymal stem cells for treating patients with knee osteoarthritis: a meta- analysis toward the establishment of effective regenerative rehabilitation. NPJ Regen Med 2018; 3: 15.
12. Gugliandolo A, Bramanti P, Mazzon E. Mesenchymal stem cells: a potential therapeutic approach for amyotrophic lateral sclerosis? Stem Cells International 2019; 2019 [online]. Dostupné z: https://www.hindawi.com/journals/sci/2019/3675627/ [cit. 2021-03-04].
13. Oh KW, Noh MY, Kwon MS, et al. Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann Neurol 2018; 84(3): 361–373.
14. Berger I, Ahmad A, Bansal A, et al. Global distribution of businesses marketing stem cell-based interventions. Cell Stem Cell 2016; 19(2): 158–162.
15. Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell 2016; 19(2): 154–157.
16. Turner L. The US direct-to-consumer marketplace for autologous stem cell interventions. Perspect Biol Med 2018; 61(1): 7–24.
17. Knoepfler PS. Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years. Regen Med 2019; 14(8): 735–740.
18. Dillon H. Inquest into the death of Sheila Drysdale [online]. Coroners Court of New South Wales 2016. Dostupné z: https://coroners.nsw.gov.au/documents/findings/2016/Findings%20 Drysdale.pdf [cit. 2021-03-04].
19. Connolly R, O’Brien T, Flaherty G. Stem cell tourism – A web-based analysis of clinical services available to international travellers. Travel Med Infect Dis 2014; 12(6, Part B): 695–701.
20. Bauer G, Elsallab M, Abou‐El‐Enein M. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. STEM CELLS Transl Med 2018; 7(9): 676–685.
21. Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer 2017; 16: 31.
22. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557–563.
23. Murray IR, Chahla J, Frank RM, et al. Rogue stem cell clinics. Bone Jt J 2020; 102-B(2): 148–154.
24. Srivastava A, Mason C, Wagena E, et al. Part 1: Defining unproven cellular therapies. Cytotherapy 2016; 18(1): 117–119.
25. Lee TL, Lysaght T, Lipworth W, et al. Regulating the stem cell industry: needs and responsibilities. Bull World Health Organ 2017; 95(9): 663–664.
26. Sleeboom-Faulkner ME. The large grey area between ‘bona fide’ and ‘rogue’ stem cell interventions – Ethical acceptability and the need to include local variability. Technol Forecast Soc Change 2016; 109: 76–86.
27. Bauer G, Elsallab M, Abou‐El‐Enein M. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell‐based interventions. Stem Cells Transl Med 2018; 7(9): 676–685.
28. Petersen A, Munsie M, Tanner C, et al. Exploiting stem cell hopes in Germany. In: Stem Cell Tourism and the Political Economy of Hope. Health, Technology and Society. Londýn: Palgrave Macmillan 2017; 101–120.
29. Státní ústav pro kontrolu léčiv. Stanovisko k použití autologních kmenových buněk určených k aplikaci do kloubu nebo do jeho okolí [online] 1. 9. 2015. Poslední změna 30. 9. 2015. Dostupné z: https://www.sukl.cz/zdravotnicka-zarizeni/stanovisko-k-pouziti- -autolognich-kmenovych-bunek-urcenych-k [cit. 2021-03-04].
30. Státní ústav pro kontrolu léčiv. Stanovisko k použití autologních kmenových buněk pro léčbu končetinové ischemie [online] 1. 9. 2015. Poslední změna 30. 9. 2015. Dostupné z: https://www.sukl. cz/zdravotnicka-zarizeni/stanovisko-k-pouziti-autolognich-kmenovych- bunek-pro-lecbu [cit. 2021-03-04].
31. Abbott A. Stem-cell ruling riles researchers. Nature 2013; 495: 418–419.
32. U.S. Food and Drug Administration. Federal court issues decision holding that US Stem Cell clinics and owner adulterated and misbranded stem cell products in violation of the law [online] 4. 6. 2019. Dostupné z: https://www.fda.gov/news-events/press-announcements/ federal-court-issues-decision-holding-us-stem-cell-clinics- -and-owner-adulterated-and-misbranded-stem [cit. 2021-03-04].
33. McGinley L, Wan W. This clinic’s experimental stem cell treatment blinded patients. Years later, the government is still trying to stop it. In: The Washington Post [online] 3. 4. 2019. Dostupné z: https://www.washingtonpost.com/national/health-science/ this-clinics-experimental-stem-cell-treatment-blinded-patients- four-years-later-the-government-is-still-trying-to-shut-itdown/ 2019/04/03/432d6d04-ff2f-11e8-83c0-b06139e540e5_story. html [cit. 2021-03-04].
34. Turner LG. Quality in health care and globalization of health services: accreditation and regulatory oversight of medical tourism companies. Int J Qual Health Care 2011; 23(1): 1–7.
35. Sipp D, Caulfield T, Kaye J, et al. Marketing of unproven stem cell-based interventions: A call to action. Sci Transl Med 2017; 9(397): eaag0426.
36. Petersen A, Seear K. Technologies of hope: techniques of the online advertising of stem cell treatments. New Genet Soc 2011; 30(4): 329–346.
37. Murdoch B, Zarzeczny A, Caulfield T. Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites’ marketing of stem cell therapies. BMJ Open 2018; 8(2): e019614.
38. Lau D, Ogbogu U, Taylor B, et al. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 2008; 3(6): 591–594.
39. Hyun I, Lindvall O, Ahrlund-Richter L, et al. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 2008; 3(6): 607–609.
40. Turner L. ClinicalTrials.gov, stem cells and ‘pay-to-participate’ clinical studies. Regen Med 2017; 12(6): 705–719.
41. Hawke B, Przybylo AR, Paciulli D, et al. How to peddle hope: an analysis of YouTube patient testimonials of unproven stem cell treatments. Stem Cell Rep 2019; 12(6): 1186–1189.
42. Patra PK, Sleeboom-Faulkner M. Recruiter-patients as ambiguous symbols of health: bionetworking and stem cell therapy in India. New Genet Soc 2011; 30(2): 155–166.
43. Kamenova K, Reshef A, Caulfield T. Representations of stem cell clinics on Twitter. Stem Cell Rev Rep 2014; 10(6): 753–760.
44. Snyder J, Turner L. Selling stem cell „treatments“ as research: prospective customer perspectives from crowdfunding campaigns. Regen Med 2018; 13(4): 375–384.
45. Einsiedel EF, Adamson H. Stem cell tourism and future stem cell tourists: policy and ethical implications. Dev World Bioeth 2012; 12(1): 35–44.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2021 Issue 6
Most read in this issue
- Quality of life of patients after orthotopic liver transplantation performed for alcoholic cirrhosis
- Can GPs ease the plight of informal carers?
- Specifics of evidence-based practice guidelines for public health domain and proposal of an algorithm for their development and evaluation
- Mesenchymal stem cells business – importance of informed consent